Sugi Predict

Sugi Predict / Targets / IFNAR1

IFNAR1

Interferon alpha/beta receptor 1 · P17181 · IFNAR1 on Sugi Atlas →

460 patent compounds predicted against IFNAR1, 208 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL30996076 SCHEMBL30996076 1.00 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL30725687) 0.97 1/20
SCHEMBL11630699 SCHEMBL11630699 0.68 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL11635394) 0.66 1/20
SCHEMBL681401 SCHEMBL681401 0.66 1/20
SCHEMBL5321295 SCHEMBL5321295 0.66 1/20
SCHEMBL29434746 SCHEMBL29434746 0.66 1/20
SCHEMBL5658941 SCHEMBL5658941 0.65 1/20
SCHEMBL14513499 SCHEMBL14513499 0.65 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1093699) 0.64 1/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL6251238) 0.64 1/20
SCHEMBL5661131 SCHEMBL5661131 0.63 1/20
SCHEMBL1399230 SCHEMBL1399230 0.62 1/20
SCHEMBL1399336 SCHEMBL1399336 0.62 1/20
SCHEMBL5659156 SCHEMBL5659156 0.62 1/20
SCHEMBL4068277 SCHEMBL4068277 0.61 1/20
SCHEMBL12728085 SCHEMBL12728085 0.61 1/20
SCHEMBL577858 SCHEMBL577858 0.60 1/20
SCHEMBL1399362 SCHEMBL1399362 0.60 1/20
SCHEMBL4068784 SCHEMBL4068784 0.60 1/20

Clinical trials — most relevant to IFNAR1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Interferon Beta 1a in Hospitalized COVID-19 Patients PHASE4UNKNOWN
Short Course of Interferon Treatment in Patients With HCV Infection PHASE4COMPLETED
Plasma Exchange in Covid-19 Patients With Anti-interferon Autoantibodies PHASE3UNKNOWN
Assessment the Activity Value of Isotretinoin (13- Cis-Retinoic Acid ) in the Treatment of COVID-19 ( Isotretinoin in Treatment of COVID-19) (Randomized) PHASE3UNKNOWN
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients PHASE2COMPLETED
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19 PHASE2COMPLETED
Early Interferon-beta Treatment for West-Nile Virus Infection PHASE2RECRUITING
Pegylated Interferon Lambda for Treatment of COVID-19 Infection PHASE2COMPLETED
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection PHASE2COMPLETED
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients PHASE2UNKNOWN
Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis PHASE2COMPLETED
Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE PHASE1/PHASE2ACTIVE_NOT_RECRUITING
An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial PHASE2COMPLETED
Immunogenicity and Safety Study of Serum-Free Avonex PHASE2COMPLETED
A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer PHASE2RECRUITING
the Investigation Into Beneficial Effects of High-dose Interferon Beta 1-a, Compared to Low-dose Interferon Beta 1-a in Moderate to Severe Covid-19 PHASE2UNKNOWN
Safety Study of Interferon Beta 1a to for Acute Stroke PHASE1COMPLETED
Phase 1b Safety Study of IMSB301 in Type 1 Interferonopathies PHASE1RECRUITING
ORB-011 In Patients With Advanced Solid Tumors PHASE1COMPLETED
Efficacy and Safety of IFN-α2β in the Treatment of Novel Coronavirus Patients EARLY_PHASE1UNKNOWN
Gene Expression Of Suppressor Of Cytokines in In Cutaneous Warts nanCOMPLETED
Prediction of Abatacept Discontinuation Using Test Reflecting Immunological Remission in Rheumatoid Arthritis nanCOMPLETED
Microbiota in COVID-19 Patients for Future Therapeutic and Preventive Approaches nanUNKNOWN
Myeloid Cells in Patients With Covid-19 Pneumonia nanUNKNOWN
Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE nanRECRUITING
Impact of the Presence of Anti-interferon Autoantibodies on the Viral Load in Severe Respiratory Infections nanRECRUITING
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 nanRECRUITING
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a IFNAR1 binder may also engage these)

ProteinNameSimilarity
Q764M8 — 1.000 Q764M8 →
Q28589 — 0.998 Q28589 →
Q04790 — 0.997 Q04790 →
Q95LF0 — 0.996 Q95LF0 →
P33896 — 0.995 P33896 →
Q14627 — 0.994 Q14627 →
O09030 — 0.993 O09030 →
Q99650 — 0.993 Q99650 →
Q5XNR9 — 0.993 Q5XNR9 →
Q8K5B1 — 0.993 Q8K5B1 →
Q65Z14 — 0.993 Q65Z14 →
Q8NI17 — 0.992 Q8NI17 →
O88786 — 0.991 O88786 →
O70535 — 0.989 O70535 →
Q9MYL0 — 0.989 Q9MYL0 →
P42703 — 0.988 P42703 →
Q8VHK6 — 0.988 Q8VHK6 →
Q8K4B4 — 0.988 Q8K4B4 →
LIFR Leukemia inhibitory factor receptor 0.987 landscape →
P78552 — 0.987 P78552 →
Q9JLU8 — 0.986 Q9JLU8 →
Q62959 — 0.986 Q62959 →
O02671 — 0.985 O02671 →
O70458 — 0.985 O70458 →
P43432 — 0.985 P43432 →
P20352 — 0.985 P20352 →
Q99665 — 0.984 Q99665 →
Q9HC73 — 0.983 Q9HC73 →
P48357 — 0.983 P48357 →
P42533 — 0.983 P42533 →